Allergan Plc (AGN)

[north40000]

IMO, both AGN and MYL will have difficulty competing against Amarin's Vascepa for Dry Eye syndrome[DES]. The DES I once had for several years[making the wear of contact lenses difficult and uncomfortable] was wiped out by Vascepa within a week of my initiation of therapy employing FDA-approved Vascepa, off-label, for unrelated conditions in April 2013:

https://dl.dropboxusercontent.com/u/57678878/EPA%20Compilation%20Rev2.5.pdf
Note item 9, page 33

http://www.fdalawblog.net/Amarin%20%2800193135%29.pdf
http://tinyurl.com/zyduacf
http://tinyurl.com/j6gjg4b

Vascepa is a comparatively low cost therapy. Dosage is 4 capsules/day, each capsule containing 1 g of 96% icosapent ethyl, an omega-3 fatty acid ester.